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trends in the excessive use of -agonist medications. RE-
SULTS: Data from 13,481 patients covered by Pharma-
care PlanC (social assistance–first dollar coverage) or PlanE
(individuals or families exceeding deductible) were ana-
lyzed. In 1996, 1898 patients (14.1%) were high users of
-agonists (12 canisters/yr) compared to 1686 (12.5%)
in 1998 (P  0.001). 1119 patients (59%) who were high
users in 1996 remained high users in 1998, 38.7% of which
continued to use 20 canisters/yr. Of those patients us-
ing  12 canisters in 1996, only 4.9% increased their use
to 12 canisters/yr in 1998. 116 patients prescribed  4
canisters in 1996 substantially increased their use to 12
canisters in 1998. Age was positively associated with the
number of canisters prescribed (r  0.21; P  0.001);
only 4% of patients 19 years used 12 canisters in
1998 compared to 16% of patients  19 yrs. Age was
also associated with increasing use over the 3 years (P 
0.001). CONCLUSIONS: This analysis suggests a trend
in asthma management towards decreasing -agonist
use. However, 10% of -agonist users in this popula-
tion continued to use excessive or increasing amounts of
-agonists despite current treatment guidelines, putting
them at greater risk for -agonist related morbidity and
mortality, and increased health care utilization.
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The Asthma-specific quality of life questionnaire (AQLQ-
NAA) is a 19-item questionnaire and has emphasis on re-
strictions in social, community and cultural activities.
Three domains of the AQLQ-NAA, community and so-
cial restrictions (CSR, 10 items), psychological and im-
pact (PIM, 4 items) and symptoms (SYM, 5 items) have
been identified using principal component analysis. OB-
JECTIVES: The purpose of this study was to identify sig-
nificant predictors of the AQLQ-NAA and each of its do-
mains. METHODS: The AQLQ-NAA was administered
to a sample of 51 adult volunteers with a diagnosis of
asthma at the Albuquerque Indian Hospital and three af-
filiated clinics. Four forward stepwise regression models
were analyzed using total AQLQ-NAA scores and each
domain score separately as the criterion variable. Six pre-
dictors (emergency care visits in the past 6 months, hos-
pitalizations in the past six months, physician visits in the
past six months, corticosteroids used in the past six
months, asthma medications used in the past six months,
and patient gender) were used in the regression models.
RESULTS: Physician visits, hospitalizations and gender
were significant predictors of total AQLQ-NAA scores
(F  10.493, P  0.05, Adjusted R2  0.388) and the
CSR domain scores (F  10.537, P  0.05, Adjusted
R2  0.389). Physician visits and hospitalizations were
significant predictors of the PIM domain scores (F 
13.368, P  0.05, Adjusted R2  0.355). Number of
asthma medications and gender were significant predic-
tors of the SYM domain scores (F  7.107, P  0.05,
Adjusted R2  0.213). CONCLUSIONS: Based on the
predictors for each of the three domains, inherent differ-
ences between the domains were observed. This study
helps further establish evidence of construct validity of
the AQLQ-NAA and its domains.
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OBJECTIVES: The purpose of this study is to evaluate
differences in asthma-related health care resource utiliza-
tion between six months preceding and following the ini-
tiation of fluticasone propionate. METHODS: Adult
asthmatics were identified through administrative medical
and pharmacy claims from an IPA model Health Mainte-
nance Organization. The study population was defined
as any identified asthmatic with continuous enrollment
who had a prescription for fluticasone propionate. Asthma-
related resource utilization was evaluated for differences
in services based on the introduction of fluticasone propi-
onate. RESULTS: A total of 199 asthmatic members
were identified with an average age of 44.7 (12.7) years
old. The majority of patients (60%) were female. There
was an inverse relationship of pharmacy costs to medical
costs from the pre- to post-fluticasone propionate period.
Pharmacy costs increased 61%, while medical costs de-
creased 71 percent. Paired-sample t-tests showed a signif-
icant decrease in the number of hospitalizations, emer-
gency room visits, and diagnostic procedures. Although
pharmacy utilization increased, it resulted in an improved
inhaled corticosteroid to beta-2 agonist ratio of 0.51 to
1.41. The net asthma-related costs declined 35%, repre-
senting a reduction of $296 per asthma study member for
the six-month period. CONCLUSIONS: In summary, the
introduction of fluticasone propionate appeared to have
a substantial impact on resource utilization and cost. Re-
sults support current literature that the use of inhaled
corticosteroids reduces the number of asthma-related
emergency room visits and hospitalizations.
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